NCT01058512 - A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Hepatitis C

Interventions

DRUG

NOV-205

"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"

Trial Locations (6)

28304

Cumberland Research Associates, LLC, Fayetteville

32256

Borland-Grooover Clinic, Jacksonville

32803

Orlando Immunology Center, Orlando

33162

Venture Research Institute, LLC, Miami

01702

MetroWest Medical Center, Framingham

01655

UMASS Memorial Medical Center, Worcester